Basic Science Discovery Leads to Clinical Trial for Patients with Chemotherapy-Resistant Form of Ovarian Cancer

Dana-Farber scientists recently uncovered a potential vulnerability in a form of ovarian cancer notoriously resistant to chemotherapy. Now they’ve opened a clinical trial involving a drug that targets that susceptibility in patients with the disease. The impetus for their research is a type of ovarian cancer with excess copies of the cyclinE1 gene (abbreviated CCNE1). … Read more

Scientists Identify Genes Tied to Increased Risk of Ovarian Cancer

Medically reviewed by Alexander Gusev, PhD A team of Dana-Farber scientists and their associates has identified 34 genes associated with an increased risk of developing earliest-stage ovarian cancer. The findings, published in the journal Nature Genetics, will both help identify women who have the highest risk of developing ovarian cancer and pave the way for identifying … Read more

‘Organoids’ Could Aid Cancer Drug Selection

Tests on living “organoids” created from patients’ ovarian cancer cells proved more accurate than DNA sequencing in predicting tumors’ sensitivity or resistance to chemotherapy drugs – and combining the two methods worked even better, say scientists at Dana-Farber Cancer Institute. The investigators report in Cancer Discovery that ovarian cancer organoids – tiny, three-dimensional spheres of cells … Read more

It’s “Unprecedented”: After Two Recurrences, Ovarian Cancer Patient is “Living a Normal Life Again”

When Fran Austin’s ovarian cancer recurred after two rounds of chemotherapy, she found herself looking for a silver lining to the dark cloud of her disease. And she found it: Genetic profiling of her tumor identified her as an ideal candidate for an immunotherapy clinical trial, which has since shrunk her tumor by 60 percent … Read more

New Online Tool Guides Genetic Testing for Lynch Syndrome

A new online assessment tool developed at Dana-Farber can help rapidly identify people who should undergo genetic testing for Lynch syndrome, an inherited disorder that greatly increases the lifetime risk of colorectal, endometrial, ovarian, stomach, and other cancers. An estimated 1 in 279 individuals – nearly a million people in the United States – carry … Read more

Gynecological Cancer Patients Find Safety, Solidarity in Support Group

Deb Petrishen says well-meaning but frustrating interactions can occur everywhere, from the grocery store to family functions. Although friends and loved ones are often sensitive and supportive, some may not know what to say to someone with stage III ovarian cancer, especially after two recurrences. Petrishen has just as much difficulty explaining her feelings. Except … Read more

Drug Prolongs Remissions in Some Relapsed Ovarian Cancers

Ed. note: Niraparib (Zejula) was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2017, as a maintenance therapy for women with ovarian, fallopian tube, or primary peritoneal cancer. This post was originally published on Oct. 21, 2016. For women with relapsed ovarian cancer that responds to platinum-based chemotherapy, a drug that hampers … Read more

An Aggressive Treatment for a Strong Patient

By Theresa Sullivan Barger After triathlete Betsy Feldmann felt pressure in her abdomen while running, which seemed “as if her insides were slipping,” she saw four doctors before being diagnosed with stage II-C ovarian cancer. Feldmann chose an aggressive approach recommended by Ursula Matulonis, MD, medical director of Gynecologic Oncology at the Susan F. Smith … Read more

Treatments for Ovarian Cancer: Finding Your Path [Infographic]

Ovarian cancer is a complex disease. Cell types, stages, and genetics play an important role for patients and their doctors as they decide which direction to take. Fortunately, patients today have many treatment options and new advances on the horizon. Physician-scientists at the Susan F. Smith Center for Women’s Cancers are leading the way in … Read more

Improving Sexual Health for Ovarian Cancer Patients

Treatment for ovarian cancer often comes with sexual side effects. Although curing the cancer is the main goal for many patients and their doctors, Sharon Bober, PhD, director of Dana-Farber’s Sexual Health Program, is focused on preserving a patient’s quality of life – including her sexual satisfaction. Bober, with co-investigators Alexi Wright, MD, MPH, a … Read more

Clinical Trial Helps Betsy Brauser Live with Ovarian Cancer

As researchers and clinicians in the Susan F. Smith Center for Women’s Cancers at Dana-Farber continue studying the benefits of a two-drug combination in slowing progression of recurrent ovarian cancer, one patient is as a beacon of hope for her caregivers – and for others facing the disease. Betsy Brauser, treated with standard chemotherapy near … Read more

Cancer Conversations Podcast – Episode #3: The Latest in Ovarian Cancer Treatment and Research

Although ovarian cancer can sometimes be difficult to treat, researchers and physicians are finding new ways to approach the disease, making way for promising alternatives to the traditional chemotherapy treatments. In this Cancer Conversations podcast episode, Ursula Matulonis, MD, Panos Konstantinopoulos, MD, PhD, and Susana Campos, MD, MPH, from the Gynecologic Oncology Program at the Susan … Read more